DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Cardiometabolic Health Congress

JULY 10, 2024

Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression. A Pioneering Journey: The Life and Legacy of Dr. George L. Bakris Dr. George L. When I heard of his passing, I felt quite sad.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52

Open Heart

JANUARY 11, 2025

We aimed to examine the impact of diabetes on 30-day mortality, 30-day readmission and compare outcomes between TAVR and sAVR. Methods Data were extracted from the Nationwide Readmissions Database from 2012 to 2017. Diabetes was present in 36.4% Conclusion Diabetes increases the risk of short-term mortality in sAVR but not TAVR.

Aortic valve 52

Aortic valve TAVR Diabetes Aortic 52